Vemlidy Dosage/Direction for Use

Testing Prior to Initiation of VEMLIDY: Prior to initiation of VEMLIDY, patients should be tested for HIV-1 infection. VEMLIDY alone should not be used in patients with HIV-1 infection [see Risk of Development of HIV-1 Resistance in Patients Coinfected with HBV and HIV-1 under Precautions].
Prior to or when initiating VEMLIDY, and during treatment with VEMLIDY on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see New Onset or Worsening Renal Impairment under Precautions].
Recommended Dosage in Adults: The recommended dosage of VEMLIDY is 25 mg (one tablet) taken orally once daily with food [see Pharmacology: Pharmacokinetics under Actions].
Dosage in Patients with Renal Impairment: No dosage adjustment of VEMLIDY is required in patients with estimated creatinine clearance greater than or equal to 15 mL per minute, or in patients with end stage renal disease (ESRD; estimated creatinine clearance below 15 mL per minute) who are receiving chronic hemodialysis. On days of hemodialysis, administer VEMLIDY after completion of hemodialysis treatment.
VEMLIDY is not recommended in patients with ESRD who are not receiving chronic hemodialysis [see Renal Impairment under Precautions and Pharmacology: Pharmacokinetics under Actions].
Dosage in Patients with Hepatic Impairment: No dosage adjustment of VEMLIDY is required in patients with mild hepatic impairment (Child-Pugh A). VEMLIDY is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment [see Hepatic Impairment under Precautions and Pharmacology: Pharmacokinetics under Actions].